Regulatory Affairs Editorial
-
Understanding The New U.K. MHRA 'Draft Guideline On Individualised mRNA Cancer Immunotherapies'
3/5/2025
The U.K.'s MHRA has released a new draft guideline outlining best practices for drug product design, CMC, and manufacturing of mRNA cancer immunotherapies using LNP delivery systems. The public comment period ends March 31.
-
Breaking Down The FDA's Latest Guidance On Electronic Systems In Clinical Investigations
2/28/2025
In October, the FDA took a significant step forward by releasing a new Q&A guidance clarifying the use of electronic systems, e-records, and e-signatures in clinical investigations.
-
U.S. Biosimilars Surge: Clinical Trials, Regulatory Shifts, And The Path To Dominance
2/28/2025
Joseph Pategou asks and answers, "Where does the U.S. biosimilar market stand now?"
-
FDA Issues Draft Guidance On The Use Of AI To Support Regulatory Decision-Making For Drug And Biological Products
2/14/2025
The U.S. FDA issued a draft guidance, Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products, on January 6, 2025. The public comment period ends April 7.
-
Day One Bio's Talks With FDA Help Secure Glioma Drug Approval
2/14/2025
Day One CMO Elly Barry, MD recounts the company's experience working with the FDA and turning a passed-over drug into its first-ever approved treatment for pediatric glioma patients.
-
Roche Diagnostics Guides New Alzheimer's Test Through Trials
2/12/2025
Roche Diagnostics’ Maria-Magdelena Patru, MD, PhD discusses their plasma test and how they’re approaching its clinical trials.
-
How PDS Biotech Approached FDA Meetings For Its Phase 3 Cancer Trial
2/11/2025
PDS Biotech CMO Kirk Shepard reveals his team’s interactions with the FDA as it sought to begin its Phase 3 trial for the treatment of HPV-positive recurrent and/or metastatic head and neck squamous cell carcinoma.
-
FDA Finalizes Guidance On The Advanced Manufacturing Technologies Designation Program
2/10/2025
The FDA released final guidance on the Advanced Manufacturing Technologies Designation Program at the end of December. This article shares a summary, analysis, and how it compares to the 2023 draft.
-
Clinical Regulatory Changes One Of Many Tailwinds For Biosimilars
2/10/2025
With an projected global market value of $35.7 billion in 2025, biosimilars are slated for considerable growth opportunities, thanks in part to clinical regulatory changes.
-
Input Needed On Using AI To Create Lay Summaries Of Trial Results
2/7/2025
CISCRP is soliciting feedback from research professionals, patients, and advocacy groups on its "Considerations for Using AI to Create Lay Summaries of Trial Results" until Feb. 18.